Source-grounded facts extracted from OPKO HEALTH, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
OPKO HEALTH, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent auditor at the 2026-06-18 meeting.
“4. The stockholders voted to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes on this proposal were as follows: For Against Abstain 535,070,921 6,120,699 2,715,188 There were no broker non-votes for the proposal.”
OPKO HEALTH, INC. shareholders approved Advisory vote to approve compensation of named executive officers at the 2026-06-18 meeting.
“3. The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Company’s 2026 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows: For Against Abstain Broker Non-Votes 446,238,170 17,487,326 413,667 79,767,645”
OPKO HEALTH, INC. shareholders approved Approval of the Company's 2026 Equity Incentive Plan at the 2026-06-18 meeting.
“2. The stockholders voted to approve the Company’s 2026 Equity Incentive Plan as disclosed in the Company’s 2026 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows: For Against Abstain Broker Non-Votes 440,096,997 23,694,041 348,125 79,767,645”
OPKO HEALTH, INC. shareholders approved Election of Directors at the 2026-06-18 meeting.
“1. All eleven nominees were elected to the Board of Directors with each director receiving votes as follows: Election of Directors For Against Abstain Broker Non-Votes Phillip Frost, M.D. 423,666,978 40,175,942 296,243 79,767,645 Jane H. Hsiao, Ph.D. 422,928,151 40,947,325 263,687 79,767,645 Elias A. Zerhouni, M.D. 420,402,573 42,561,617 1,174,973 79,767,645 Steven D. Rubin 409,356,877 54,519,219 263,067 79,767,645 Gary J. Nabel, M.D., Ph.D. 420,083,341 43,643,796 412,026 79,767,645 Prem A. Lachman, M.D. 428,600,587 35,002,548 536,028 79,767,645 Roger J. Medel, M.D. 428,125,427 35,411,814 601,922 79,767,645 John A. Paganelli 398,032,505 65,734,019 372,639 79,767,645 Richard C. Pfenniger, Jr. 424,416,857 39,352,175 370,131 79,767,645 Subbarao V. Uppaluri, Ph.D. 454,992,813 8,481,656 664,694 79,767,645 Alice Lin-Tsing Yu, M.D., Ph.D. 418,457,740 45,287,103 394,320 79,767,645”
OPKO HEALTH, INC. reported the three months ended March 31, 2026 results: revenue $124.2 million, net income $54.8 million, EPS $0.07 per share.
“each is responsible for 50% of the program's development costs. First Quarter Financial Results • Consolidated: Consolidated total revenues for the first quarter of 2026 were $124.2 million compared with $149.9 million for the 2025 period, with the decrease principally resulting from the sale of certain BioReference assets in 2025. Operating loss for the first”
OPKO HEALTH, INC. completed a disposition involving Laboratory Corporation of America Holdings for approximately $237,500,000 in cash (closed 2024-09-16).
“On September 16, 2024, the parties to the Purchase Agreement consummated the Transaction, and the Company received approximately $237,500,000 in cash, including escrow, subject to certain adjustments as set forth in the Purchase Agreement.”
OPKO HEALTH, INC. reported three months ended March 31, 2024 results: revenue $173.7 million, net income $81.8 million, or $0.12 per share, EPS $0.12 per share.
“was $34.4 million in the first quarter of 2024 compared with $40.0 million in the 2023 period. ● Consolidated: Consolidated total revenues for the first quarter of 2024 were $173.7 million compared with $237.6 million for the comparable period of 2023. Operating loss for the first quarter of 2024 increased to $71.5 million from $30.6 million for the 2023 quarter,”
OPKO HEALTH, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-03-28 meeting.
“4. The stockholders voted to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes on this proposal were as follows: For Against Abstain Broker Non-Votes 519,634,618 10,186,987 1,476,226 0”
OPKO HEALTH, INC. shareholders approved Non-binding advisory vote to approve the compensation of the named executive officers at the 2024-03-28 meeting.
“3. The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Company’s 2024 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows: For Against Abstain Broker Non-Votes 431,121,613.12 13,954,192 1,522,264.675 84,699,761”
OPKO HEALTH, INC. shareholders approved Amendment to the Company’s amended and restated certificate of incorporation to increase the authorized number of shares of the Company’s Common Stock that the Company may issue from 1,000,000,000 shares to 1,250,000,000 shares at the 2024-03-28 meeting.
“2. The stockholders voted to approve an amendment to the Company’s amended and restated certificate of incorporation to increase the authorized number of shares of the Company’s Common Stock that the Company may issue from 1,000,000,000 shares to 1,250,000,000 shares as disclosed in the 2024 Proxy Statement for the Annual Meeting. The votes on the OPKO authorized share increase proposal were as follows: For Against Abstain 492,393,778 37,918,739 985,314”
OPKO HEALTH, INC. shareholders approved Election of Directors at the 2024-03-28 meeting.
“1. All eleven nominees were elected to the Board of Directors with each director receiving votes as follows: Election of Directors For Against Abstain Broker Non-Votes Phillip Frost, M.D. 417,952,041 22,474,563 6,171,466 84,699,761 Jane H. Hsiao, Ph.D. 413,880,317 26,420,093 6,297,660 84,699,761 Elias A. Zerhouni, M.D. 414,360,287 26,147,182 6,090,601 84,699,761 Steven D. Rubin 409,265,433 31,259,959 6,072,678 84,699,761 Gary J. Nabel, M.D., Ph.D. 414,266,144 26,217,873 6,114,053 84,699,761 Richard M. Krasno, Ph.D. 433,053,909 12,897,229 646,932 84,699,761 Prem A. Lachman, M.D. 435,390,598 10,489,096 718,376 84,699,761 Roger J. Medel, M.D. 435,237,621 10,618,192 742,257 84,699,761 John A. Paganelli 415,788,107 29,404,640 1,405,323 84,699,761 Richard C. Pfenniger, Jr. 419,052,214 26,216,424 1,329,432 84,699,761 Alice Lin-Tsing Yu, M.D., Ph.D. 438,269,264 7,742,819 585,987 84,699,761”
OPKO HEALTH, INC. entered into Asset Purchase Agreement with Laboratory Corporation of America Holdings valued at approximately $237,500,000 in cash (effective 2024-03-27).
“On March 27, 2024, OPKO Health, Inc., a Delaware corporation (“ OPKO ”), its wholly owned subsidiary, BioReference Health, LLC (“ BioReference ” and together with OPKO, “ Seller ”), and Laboratory Corporation of America Holdings, a Delaware corporation (“ Buyer ”), entered into an Asset Purchase Agreement (the “ Purchase Agreement ”).”
OPKO HEALTH, INC. reported three and 12 months ended December 31, 2023 results: revenue $181.9 million, net income Net loss for the fourth quarter of 2023 was $65.5 million, or $0.09 per share, EPS $0.09 per share.
“of revenue adjustments, compared with an operating loss of $23.1 million in the 2022 period. ● Consolidated: Consolidated total revenues for the fourth quarter of 2023 were $181.9 million compared with $185.4 million for the comparable 2022 period. Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for”
Alexis Borisy departed as Director at OPKO HEALTH, INC..
“On February 9, 2024, Alexis Borisy, a member of the Board of Directors (the “ Board ”) of OPKO Health, Inc. (the “ Company ”), and a member of Compensation Committee of the Board, informed the Board that he does not intend to stand for reelection at the Company’s 2024 Annual Meeting of Stockholders.”
OPKO HEALTH, INC. terminated 4.50% Convertible Senior Notes due 2025 with certain holders of the Company’s outstanding 4.50% Convertible Senior Notes due 2025 valued at Repurchase and retirement of approximately $144.4 million aggregate principal amount (effective 2024-01-09).
“Also, contemporaneously with the pricing of the 144A Notes, the Company entered into separate, privately negotiated transactions with certain holders of the Company’s outstanding 4.50% Convertible Senior Notes due 2025 to repurchase, on the Closing Date, approximately $144.4 million aggregate principal amount of such notes, all of which notes were retired by the Company upon its acquisition thereof.”
OPKO HEALTH, INC. entered into 144A Note Purchase Agreement and Affiliate Note Purchase Agreement with J.P. Morgan Securities LLC and Affiliate Purchasers (Frost Gamma Investments Trust and Jane H. Hsiao) valued at $301.1 million aggregate principal amount of 3.75% Convertible Senior Notes due 2029 ($230 million 1 (effective 2024-01-09).
“On January 9, 2024 (the “ Closing Date ”), OPKO Health, Inc., a Delaware corporation (the “ Company ”), completed its previously announced private offering of $230.0 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2029 (the “ 144A Notes ”) in accordance with the terms of a note purchase agreement (the “ 144A Note Purchase Agreement ”) entered into on January 4, 2024 by and between by the Company and J.P. Morgan Securities LLC (the “ Initial Purchaser ”). The $230.0 million aggregate principal amount of 144A Notes includes $30.0 million aggregate principal amount of 144A Notes purchased on the Closing Date by the Initial Purchaser in accordance with its exercise in full of its option to purchase additional 144A Notes under the 144A Note Purchase Agreement. Additionally, on the Closing Date, the Company issued and sold approximately $71.1 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2029 (the “ Affiliate Notes ” and, together”
OPKO HEALTH, INC. reported the quarter ended September 30, 2023 results: revenue $178.6 million.
“Consolidated total revenues for the third quarter of 2023 were $178.6 million”
OPKO HEALTH, INC. reported the quarter ended June 30, 2023 results: revenue $265.4 million, net income $19.6 million, or $0.03 per share, EPS $0.03 per share.
“BioReference continues to implement cost-reduction initiatives as it works toward profitability. ● Consolidated: Consolidated total revenues for the second quarter of 2023 were $265.4 million compared with $309.9 million for the comparable period of 2022. Operating income for the second quarter of 2023 was $7.0 million compared with an operating loss of $10.7 million”
OPKO HEALTH, INC. amended Waiver and Amendment No. 2 with JPMorgan Chase Bank, N.A., as administrative agent for the lenders (effective 2023-06-29).
“On June 29, 2023, BioReference Health, LLC, a Delaware limited liability company (“ BRH ”), a subsidiary of OPKO Health, Inc. (the “ Company ”), together with the other parties thereto, entered into a Waiver and Amendment No. 2 (the “ Amendment ”) to the Amended and Restated Credit Agreement (the “ Amended Credit Agreement ”), dated as of August 30, 2021, by and among BRH, certain of its subsidiaries, as borrowers or guarantors, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent for the lenders.”
OPKO HEALTH, INC. shareholders approved ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-22 meeting.
“The stockholders voted to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes on this proposal were as follows: For Against Abstain Broker Non-Votes 550,763,909 5,514,961 1,088,237 0”
OPKO HEALTH, INC. shareholders approved selection of one year as frequency of non-binding advisory vote on executive compensation at the 2023-06-22 meeting.
“The stockholders selected one year as the frequency with which the stockholders are provided a non-binding advisory vote on Say on Pay in future years. The votes on this proposal were as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 439,223,605 1,033,695 6,933,736 6,354,426 103,821,645”
OPKO HEALTH, INC. shareholders approved non-binding advisory vote on compensation of named executive officers at the 2023-06-22 meeting.
“The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Company’s 2023 Proxy Statement for the Annual Meeting ("Say on Pay"). The votes on this proposal were as follows: For Against Abstain Broker Non-Votes 437,636,656 14,823,803 1,085,003 103,821,645”
OPKO HEALTH, INC. shareholders approved Election of Directors at the 2023-06-22 meeting.
“All twelve nominees were elected to the Board of Directors with each director receiving votes as follows: Election of Directors For Against Abstain Broker Non-Votes Phillip Frost, M.D. 379,317,162 74,045,929 182,371 103,821,645 Jane H. Hsiao, Ph.D. 376,333,526 74,783,417 2,428,516 103,821,645 Elias A. Zerhouni, M.D. 374,789,049 72,680,790 6,075,623 103,821,645 Steven D. Rubin 372,904,884 80,358,638 276,940 103,821,645 Gary J. Nabel, M.D., Ph.D. 344,928,159 75,168,839 33,448,464 103,821,645 Alexis Borisy 390,808,455 54,496,718 8,240,289 103,821,645 Richard M. Krasno, Ph.D. 443,928,010 6,849,617 2,767,835 103,821,645 Prem A. Lachman, M.D. 405,262,395 48,129,851 153,216 103,821,645 Roger J. Medel, M.D. 405,420,677 47,970,760 154,025 103,821,645 John A. Paganelli 370,203,909 80,525,601 2,815,952 103,821,645 Richard C. Pfenniger, Jr. 370,802,956 80,317,503 2,425,003 103,821,645 Alice Lin-Tsing Yu, M.D., Ph.D. 351,259,466 95,571,415 6,714,591 103,821,645”
OPKO HEALTH, INC. reported the three months ended March 31, 2023 results: revenue $237.6 million, net income $18.3 million, EPS $0.02 per share.
“Consolidated total revenues for the first quarter of 2023 were $237.6 million compared with $329.2 million for the comparable period of 2022.”
OPKO HEALTH, INC. entered into License and Research Collaboration Agreement with Merck Sharp & Dohme LLC valued at $50 million initial payment, up to $872.5 million milestones, tiered royalties high single digits to (effective 2023-03-08).
“On March 8, 2023, ModeX Therapeutics, Inc. (“ ModeX ”), a wholly-owned subsidiary of OPKO Health, Inc. (“ OPKO ”), OPKO with respect to certain sections, and Merck Sharp & Dohme LLC (“ Merck ”) entered into a License and Research Collaboration Agreement (the “ Agreement ”) pursuant to which Merck obtained from ModeX a license to certain patent rights and know-how of ModeX.”
OPKO HEALTH, INC. amended convertible notes at 5% maturing extend the maturity to January 31, 2025.
“On or about February 10, 2023, the Company amended the Notes to extend the maturity to January 31, 2025, and to reset the conversion price to the 10 day volume weighted average price immediately preceding the date of the amended note, plus a 25% conversion premium, or $1.66.”
OPKO HEALTH, INC. amended 5% Convertible Promissory Notes with each holder of a Note (effective 2023-02-10).
“On or about February 10, 2023, the Company amended the Notes to extend the maturity to January 31, 2025, and to reset the conversion price to the 10 day volume weighted average price immediately preceding the date of the amended note, plus a 25% conversion premium, or $1.66.”
OPKO HEALTH, INC. reported third quarter of 2022 results: revenue Consolidated total revenues for the third quarter of 2022 were $179.7 million, net income Net loss for the third quarter of 2022 was $86.1 million, EPS $0.11 per share.
“Net loss for the third quarter of 2022 was $86.1 million, or $0.11 per share, compared with net income of $28.7 million, or $0.04 per diluted share, for the 2021 quarter.”
Jon R. Cohen retired as Senior Vice President and Executive Chairman and Chief Executive Officer at OPKO HEALTH, INC..
“On August 16, 2022, Dr. Jon R. Cohen, retired from his positions as Senior Vice President of OPKO Health, Inc., a Delaware corporation (the “ Company ”), and Executive Chairman and Chief Executive Officer of BioReference Health, LLC”
Alexis Borisy was appointed as director at OPKO HEALTH, INC..
“On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.”
Gary Nabel was appointed as Chief Innovation Officer and a director at OPKO HEALTH, INC..
“On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.”
Elias Zerhouni was appointed as President and Vice Chairman of the Board at OPKO HEALTH, INC..
“On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.”
Dr. Robert Fishel retired as Director at OPKO HEALTH, INC..
“On January 21, 2022, Dr. Robert Fishel notified OPKO Health, Inc. (the “ Company ”), that he was retiring from service on the Company’s Board of Directors (the “ Board ”), effective January 21, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.